• SPX
  • $5,968.79
  • 0.34 %
  • $20.08
  • DJI
  • $44,232.15
  • 0.82 %
  • $361.79
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,004.12
  • 0.17 %
  • $31.70
CNS Pharmaceuticals, Inc. (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals, Inc. (CNSP) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.12

-$0.01

(-7.77%)

Day's range
$0.11
Day's range
$0.13
50-day range
$0.1
Day's range
$0.3699
  • Country: US
  • ISIN: US18978H2013
52 wk range
$0.1
Day's range
$121
  • CEO: Mr. John Michael Climaco Esq., J.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -21.30
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (CNSP)
  • Company CNS Pharmaceuticals, Inc.
  • Price $0.12
  • Changes Percentage (-7.77%)
  • Change -$0.01
  • Day Low $0.11
  • Day High $0.13
  • Year High $121.00

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/31/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.50
  • High Stock Price Target $0.50
  • Low Stock Price Target $0.50
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$391.00
  • Trailing P/E Ratio -0.01
  • Forward P/E Ratio -0.01
  • P/E Growth -0.01
  • Net Income $-18,851,226

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

CNS Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the CNS Pharmaceuticals, Inc. stock price today?

    Today's price of CNS Pharmaceuticals, Inc. is $0.12 — it has decreased by -7.77% in the past 24 hours. Watch CNS Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does CNS Pharmaceuticals, Inc. release reports?

    Yes, you can track CNS Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the CNS Pharmaceuticals, Inc. stock forecast?

    Watch the CNS Pharmaceuticals, Inc. chart and read a more detailed CNS Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is CNS Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by CNS Pharmaceuticals, Inc. stock ticker.

  • How to buy CNS Pharmaceuticals, Inc. stocks?

    Like other stocks, CNSP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is CNS Pharmaceuticals, Inc.'s EBITDA?

    CNS Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in CNS Pharmaceuticals, Inc.’s financial statements.

  • What is the CNS Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in CNS Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including CNS Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. CNS Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for CNS Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review CNS Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.